StockGuru Blog: Vicor Technologies, Inc. (OTCBB: VCRT)
Vicor Technologies, Inc. (OTCBB: VCRT)
LEVEL 1 TRADE IDEA
Dear Members,
Vicor Technologies, Inc. (OTCBB: VCRT) has a strong scientific foundation and has been embraced internationally.
This Company is led by a team with incredible experience. They know what they are doing.
You want to know that the fantastic science Vicor brings to the table will not fail because of lack of business experience.
I am a huge fan of the fact that their initial roll out was designed to deliver feed back to the company.
Vicor is in the very advanced stages for a Bio-Tech holding.
Management and Scientific Advisory Board
David H. Fater
President, Chief Executive Officer, Chief Financial Officer, Director
Joined Vicor in 2002, from ALDA & Associates International Inc., a business and financial consulting firm specializing in healthcare and life sciences.
Prior to forming ALDA & Associates in 1993, Mr. Fater held senior executive positions with three public healthcare companies. He led the initial public offering process for BMJ Medical Management, Inc. (1997-1999) and Community Care of America (1995-1996), and led Coastal Physician Group, Inc. (1993-1995) to a NYSE listing and $1 Billion market capitalization. Before this, Mr. Fater was employed by Ernst & Young, where he completed his 24-year tenure as a Senior International Partner advising senior management and boards of directors (1969-1992).
Mr. Fater is a certified public accountant in Georgia, Illinois, North Carolina, and New York. He holds a BS in Accounting from the University of North Carolina.
James E. Skinner, Ph.D.
Vice President, Director of Grant Research, Director
Founding Vicor in August, 2000, Dr. Skinner has extensive experience both as a scientist and manager of large research and development projects. He is the Director of the Delaware Water Gap Science Institute, a non-profit medical research organization devoted to the development of medical devices and pharmaceuticals. Prior to founding the Delaware Water Gap Science Institute, Dr. Skinner was Associate Director of the Totts Gap Medical Research Laboratories, Inc. (1969-1997). Earlier, he was a Professor and Researcher at Baylor College of Medicine in Houston (1969-1993) and recipient of numerous research grants from the National Institutes of Health.
Dr. Skinner holds a PhD in Neuroscience from the University of California at Los Angeles and a BA in Pre-Med, Physics, and Physiological Psychology from Pomona College.
Jerry M. Anchin, Ph.D.
Vice President, Director of Research and Development, Director
Dr. Anchin has more than 30 years of experience in the fields of immunology, molecular biology, drug discovery and protein chemistry. Prior to founding Vicor in 2000, Dr. Anchin was employed by Ciblex Pharmaceuticals (1998-2000), where he became group leader of the drug discovery program that led to the discovery of novel small molecules for use in the prevention of asthma. Earlier, he held positions at Prism Pharmaceuticals (1996-1998), and Immuno Pharmaceuticals (1993-1996). Before that, he was Head of Assay Development and Manufacturing at International Immunoassay Labs (1991-1998), where he was instrumental in designing a novel assay for the detection of the protein creatine kinase released during acute myocardial infarction.
Dr. Anchin holds patents for 14 immunoassay and drug discovery platforms; he has an additional 16 patents pending. Dr. Anchin earned a PhD in Immunology from Texas A&M University and a BA in Cell Biology from the University of California at Santa Barbara.
Daniel N. Weiss, M.D., F.A.C.C.
Chief Medical Officer
With Vicor since 2004, Dr. Weiss has extensive experience as a practicing cardiologist and electrophysiologist. He is a partner in Florida Arrhythmia Consultants and was the director of several hospital electrophysiology laboratories. He has also served as a consultant to several Fortune 500 medical device companies, including Medtronic, St. Jude Medical and Guidant. In addition, he served as clinical investigator in the MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial) and SCDHeFT (Sudden Cardiac Death Heart Failure Trial) clinical trials.
Dr. Weiss received his MD with Distinction in Research from the Mount Sinai School of Medicine where he received the Nathan A. Seltz Award for research in Cardiovascular and Renal Disease. He holds a BSE cum laude in Electrical Engineering and Computer Science from Princeton University.
Thomas J. Bohannon
Chief Accounting Officer
Thomas J. Bohannon was appointed to serve as the Chief Accounting Officer of the Company effective as of December 28, 2008. Mr. Bohannon has been in the accounting and financial field for more than 40 years. Mr. Bohannon worked as a senior manager at Ernst & Young in Atlanta from 1968 until 1978 where he specialized in financial and SEC reporting before becoming the partner in charge of audit and review services for Pappadakis, Nelson & Bohannon from 1978-1991. Since 1992, he has focused on his own consulting practice, serving as the financial officer for a variety of companies in the Southeast United States.
The current directors of the Company are David H. Fater (2002) and James E. Skinner (2000) (Class I), Jerry M. Anchin (2003) and Frederick M. Hudson (2008) (Class II), and Dr. Edward Wiesmeier (2004)and Joseph C. Franchetti (2008) (Class III). The Class I Directors’ term expires at the 2011 Annual Meeting. The Class II Directors’ term expires at the 2012 Annual Meeting. The Class III Directors’ term expires at the 2010 Annual Meeting.
Edward Wiesmeier, MD
Dr. Wiesmeier has been a member of the Company’s board of directors since October 2004. From 1974 to 2007, Dr. Wiesmeier was at UCLA where during that time he served as Clinical Professor of Obstetrics & Gynecology at the UCLA School of Medicine and Assistant Vice Chancellor for Student Development and Health. Presently he is Clinical Professor/Voluntary in the Dept. of Reproductive Medicine at the UCSD School of Medicine. Dr. Wiesmeier serves as Chairman of the Company’s Scientific Advisory Board.
Frederick M. Hudson
At the time of his retirement from KPMG, Mr. Hudson was a partner in charge of the firm’s Mid-Atlantic Health Care Practice (1969-2006). He is a Director on the Board of Financial Administration of the Catholic Archdiocese of Baltimore, the Board of Sponsors of Loyola College Sellinger School of Business and Management, and the Board of Trustees of the Maryland Historical Society. He is Chairman of the Audit Committee of the Board of Directors of Paradigm Management Services, LLC, and Remedi Health Services, Inc., and a member of the Audit and Finance Committee of the Board of Directors of GBMC Healthcare, Inc., and its affiliate, the Greater Baltimore Medical Center. Mr. Hudson is a graduate of Loyola College.
Joseph C. Franchetti
Mr. Franchetti is, and has been, a consultant, director, and advisor to several healthcare/medical device companies, including start-ups, in the cardiology/cardiovascular and life sciences areas. He is currently Vice Chairman of CVAC Health Systems, Inc. Earlier, he was President and Chief Executive Officer of Cohn Medical Instruments Corp. (now Omron), a Japanese-owned, global leader in non-invasive blood pressure, and physiological and vital sign monitoring and diagnosis. He founded and was Chief Executive Officer of Bio-Chem Laboratory Systems Inc., and a Corporate and International Vice President and General Manager for Technicon (now Siemens) and Narco Scientific (now Respirionics). He is a Trustee Emeritus of Southwest Research Institute of Texas. Mr. Franchetti is a graduate of the Wharton School of the University of Pennsylvania.
Scientific Advisory Board
Vicor’s Scientific Advisory Board gives it access to some of the most accomplished professionals in the life sciences. In addition to others, Vicor’s Scientific Advisory Board includes such significant thought leaders as:
Mark E. Josephson, MD
• Chief of Cardiology, Beth Israel Deaconess Medical Center
• One of the world’s leading experts on arhythmias
• Author, Clinical Cardiac Electrophysiology
• Scientific advisor to over twenty companies
Hein J. J. Wellens, MD
• Chairman & Professor, Cardiology Department, Academisch Ziekenhuis Maastricht, the Netherlands
• Director, Interuniversity Cardiology Institute
• Member, Netherlands Academy of Arts and Sciences
• Visiting Lecturer, Harvard Medical School.
Richard M. Luceri, MD, FACC
• Recently retired Director, Interventional Arrhythmia Center, Holy Cross Hospital
• Clinical Investigator, MADIT-II (MultiCenter Automatic Defibrillator Implantation Trial)
• Author, SCD-HeFT (Sudden Cardiac Death Heart Failure Trial).
Robert G. Hauser, MD, FACC, FHRS
• Senior Consulting Cardiologist, Minneapolis Heart Institute
• Chairman, Cardiovascular Services Division, Abbott Northwestern Hospital.
• Former CEO, Cardiac Pacemakers, Inc. (Eli Lilly subsidiary acquired by Guidant Corporation)
Jonathan Kaplan, MD, MPH
• Medical Director, Fidelis Care New York
• Former Corporate Medical Director, Excellus Blue Cross Blue Shield.
David Chazanovitz
• Former President/CEO, Alveolus, Inc.
• Former CEO, Cambridge Heart, Inc.
Edward F. Lundy, MD, PhD
• Chief of Cardiothoracic Surgery, Active International Cardiovascular Institute at Good Samaritan Hospital
• Ph.D. in physiology with focus on altered states physiologies (hibernation)
• Accomplished trauma surgeon
Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com
Thank you,
John Pentony
Publisher, StockGuru.com
Introduction
Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise.
This biotechnology company is focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i™ nonlinear algorithm and software which is:
- Highly accurate
- Provides user friendly data acquisition
- Effective for trauma triage easily deployed in a portable monitor
- Provides a simple noninvasive test for identifying patients at risk of sudden cardiac death
- Provides a simple noninvasive test for identifying patients with Diabetic Autonomic Neuropathy
 The PD2i Algorithm and software risk stratifies target populations to predict future pathological events. As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%.
The advantage of the PD2i™ nonlinear algorithm is that it typically uses recordings made at rest and does not require stress-testing or any active participation from the patient. The test is relatively impervious to data non-stationarities and artifacts, setting it apart from other measures with unparalleled sensitivity.
A large physician shareholder base represents the early adoptees of this Company.
Vicor’s PD2i™ Nonlinear Algorithm is:
- A new vital sign with the ability to actually save lives in both combat and civilian setting
- The PD2i Analyzer™ can capture and display Heart Rate Variability (see defined below) in patients at rest and during paced respiration and controlled exercise.
- Able to identify trauma victims in need of an immediate lifesaving intervention
- Able to be used along with other clinical data to identify patients at risk of sudden cardiac death
- Able to be used along with other clinical data to identify patients who have autonomic dysfunction
- Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed
- Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting
- Not derailed in delivering actionable results by noisy raw EKG data
- Functional in trauma environments and battlefield situations
READ THE FULL STOCKGURU PROFILE HERE:
http://www.stockguru.com/about/vicor/
|
Live Twitter Alerts All Market Day
Our Twitter Feed includes all live posts from StockGuru.com.
Featured on StockGuru
While we cover many companies, here are our current featured profiles on StockGuru:
NXT Nutritionals
(OTCBB: NXTH)
Affinity Mediaworks Corp.
(OTCBB: AFFW)
Arkanova Energy Corporation (OTCBB: AKVA)
Hi Score Corporation.
(OTC: HSCO)
Halo Companies, Inc..
(OTCBB: HALN)
Vicor Technologies, Inc.
(OTCBB: VCRT)
Medizone International
(OTCBB: MZEI)
Skinvisible, Inc.
(OTCBB: SKVI)
StockGuru Spotlight Alerts
Here are our latest Spotlight Alerts. Note that we typically do NOT email these to members. You must visit the site at THIS LINK to keep up to date; or you may subscribe to THIS RSS FEED.
Suggest a Client:
Do you know a great company that simply must be featured on StockGuru or Shareholder Vision?
Suggest it to us.
Email: john@stockguru.com
Tel: (469) 252-3031.
|
